123 related articles for article (PubMed ID: 38613996)
1. The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis.
Cavaco M; Pérez-Peinado C; Valle J; Silva RDM; Gano L; Correia JDG; Andreu D; Castanho MARB; Neves V
Biomed Pharmacother; 2024 May; 174():116573. PubMed ID: 38613996
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY
J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889
[TBL] [Abstract][Full Text] [Related]
3. The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics.
Oliveira FD; Cavaco M; Figueira TN; Valle J; Neves V; Andreu D; Gaspar D; Castanho MARB
FEBS J; 2022 Mar; 289(6):1603-1624. PubMed ID: 34679257
[TBL] [Abstract][Full Text] [Related]
4. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
[TBL] [Abstract][Full Text] [Related]
5. αB-crystallin: a novel regulator of breast cancer metastasis to the brain.
Malin D; Strekalova E; Petrovic V; Deal AM; Al Ahmad A; Adamo B; Miller CR; Ugolkov A; Livasy C; Fritchie K; Hamilton E; Blackwell K; Geradts J; Ewend M; Carey L; Shusta EV; Anders CK; Cryns VL
Clin Cancer Res; 2014 Jan; 20(1):56-67. PubMed ID: 24132917
[TBL] [Abstract][Full Text] [Related]
6. Insights into the Steps of Breast Cancer-Brain Metastases Development: Tumor Cell Interactions with the Blood-Brain Barrier.
Hamester F; Stürken C; Saygi C; Qi M; Legler K; Gorzelanny C; Robador JR; Schmalfeldt B; Laakmann E; Müller V; Witzel I; Oliveira-Ferrer L
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163822
[TBL] [Abstract][Full Text] [Related]
7. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.
Feng Z; Xia Y; Gao T; Xu F; Lei Q; Peng C; Yang Y; Xue Q; Hu X; Wang Q; Wang R; Ran Z; Zeng Z; Yang N; Xie Z; Yu L
Cell Death Dis; 2018 Sep; 9(10):1006. PubMed ID: 30258182
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain.
Avraham HK; Jiang S; Fu Y; Nakshatri H; Ovadia H; Avraham S
J Pathol; 2014 Feb; 232(3):369-81. PubMed ID: 24421076
[TBL] [Abstract][Full Text] [Related]
9.
Cavaco M; Valle J; da Silva R; Correia JDG; Castanho MARB; Andreu D; Neves V
Curr Pharm Des; 2020; 26(13):1495-1506. PubMed ID: 32053069
[TBL] [Abstract][Full Text] [Related]
10. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases.
Contreras-Zárate MJ; Day NL; Ormond DR; Borges VF; Tobet S; Gril B; Steeg PS; Cittelly DM
Oncogene; 2019 Jun; 38(24):4685-4699. PubMed ID: 30796353
[TBL] [Abstract][Full Text] [Related]
11. Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules.
Cavaco M; Frutos S; Oliete P; Valle J; Andreu D; Castanho MARB; Vila-Perelló M; Neves V
ACS Med Chem Lett; 2021 Nov; 12(11):1663-1668. PubMed ID: 36060671
[TBL] [Abstract][Full Text] [Related]
12. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
13. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
[TBL] [Abstract][Full Text] [Related]
14. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.
Demeule M; Charfi C; Currie JC; Larocque A; Zgheib A; Kozelko S; Béliveau R; Marsolais C; Annabi B
Cancer Sci; 2021 Oct; 112(10):4317-4334. PubMed ID: 34314556
[TBL] [Abstract][Full Text] [Related]
15. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
16. Synergistic tumor microenvironment targeting and blood-brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy.
Li M; Shi K; Tang X; Wei J; Cun X; Long Y; Zhang Z; He Q
Nanomedicine; 2018 Aug; 14(6):1833-1843. PubMed ID: 29800759
[TBL] [Abstract][Full Text] [Related]
17. Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer.
Azari M; Bahreini F; Uversky VN; Rezaei N
Biochem Pharmacol; 2023 Apr; 210():115459. PubMed ID: 36813121
[TBL] [Abstract][Full Text] [Related]
18. Peptide density targets and impedes triple negative breast cancer metastasis.
Liu D; Guo P; McCarthy C; Wang B; Tao Y; Auguste D
Nat Commun; 2018 Jul; 9(1):2612. PubMed ID: 29973594
[TBL] [Abstract][Full Text] [Related]
19. Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.
Chen L; Zeng D; Xu N; Li C; Zhang W; Zhu X; Gao Y; Chen PR; Lin J
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41889-41897. PubMed ID: 31615203
[TBL] [Abstract][Full Text] [Related]
20. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
